Salix Pharmaceuticals and Eisai have entered into a multi-year co-promotion deal to promote Salix's ulcerative colitis treatement Colazal (balsalazide disodium).
Financial terms of the deal were not disclosed.
Eisai's primary care and specialty sales forces will help Salix promote Colazal to primary care physicians and gastroenterologists. Approximately 600 Eisai sales reps will be added to the field force of 96 Salix reps, beginning in late October, an Eisai spokeswoman told MM&M.
Eisai also has exclusive rights to be involved in promotion of an 1100 mg. version of Colazal, pending product approval, Eisai said.